Predicting the Need for Biopsy to Detect Clinically Significant Prostate Cancer in Patients with a Magnetic Resonance Imaging–detected Prostate Imaging Reporting and Data System/Likert ≥3 Lesion: Development and Multinational External Validation of the Imperial Rapid Access to Prostate Imaging and Diagnosis Risk Score
: Peters Max, Eldred-Evans David, Kurver Piet, Falagario Ugo Giovanni, Connor Martin J., Shah Taimur T., Verhoeff Joost J.C., Taimen Pekka, Aronen Hannu J., Knaapila Juha, Montoya Perez Ileana, Ettala Otto, Stabile Armando, Gandaglia Giorgio, Fossati Nicola, Martini Alberto, Cucchiara Vito, Briganti Alberto, Lantz Anna, Picker Wolfgang, Haug Erik Skaaheim, Nordström Tobias, Tanaka Mariana Bertoncelli, Reddy Deepika, Bass Edward, van Rossum Peter S.N., Wong Kathie, Tam Henry, Winkler Mathias, Gordon Stephen, Qazi Hasan, Boström Peter J., Jambor Ivan, Ahmed Hashim U.
Publisher: Elsevier B.V.
: 2022
: European Urology
: European Urology
: 82
: 5
: 559
: 568
: 1873-7560
DOI: https://doi.org/10.1016/j.eururo.2022.07.022
: https://doi.org/10.1016/j.eururo.2022.07.022
: https://research.utu.fi/converis/portal/detail/Publication/176376695
Background: Although multiparametric magnetic resonance imaging (MRI) has high
sensitivity, its lower specificity leads to a high prevalence of false-positive lesions requir-
ing biopsy.
Objective: To develop and externally validate a scoring system for MRI-detected Prostate
Imaging Reporting and Data System (PIRADS)/Likert 3 lesions containing clinically sig-
nificant prostate cancer (csPCa).
Design, setting, and participants: The multicentre Rapid Access to Prostate Imaging and
Diagnosis (RAPID) pathway included 1189 patients referred to urology due to elevated
age-specific prostate-specific antigen (PSA) and/or abnormal digital rectal examination (DRE); April 27, 2017 to October 25, 2019.
